Advertisement

Extracorporeal Blood Purification Techniques: Plasmapheresis and Hemoperfusion

  • Hans Gurland
  • Walter Samtleben
  • Michael J. Lysaght
  • James F. Winchester

Abstract

This chapter will focus on techniques other than dialysis for removal of chemical toxins (endogenous or exogenous), immune toxins, or other naturally occurring biochemical substances considered to produce disease. Plasmapheresis is the process of removal of plasma (by mechanical, immunoprecipitation, cryoprecipitation, or filtration techniques) which contains the substance in question. Hemoperfusion is the passage of blood over sorbent agents for removal of harmful products

Keywords

Lupus Nephritis Plasma Exchange Hemolytic Uremic Syndrome Fresh Freeze Plasma Thrombotic Thrombocytopenic Purpura 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adam WS, Blahd WH, Bassett SH: A method of human plasmapheresis. Proc Soc Exp Biol Med 80: 377, 1952Google Scholar
  2. 2.
    Conway N, Walker JM: Treatment of macroglobulinaemia. Br Med J 2: 1296, 1962PubMedGoogle Scholar
  3. 3.
    Millward BL, Hoeltge GA: The historical development of automated hemapheresis. J Clin Apheresis 1: 25, 1982PubMedGoogle Scholar
  4. 4.
    Gloeckner WM, Sieberth HG: Plasma filtration, a new method of plasma exchange. Proc Eur Soc Artif Organs 4:214, 1978Google Scholar
  5. 5.
    Gurland HJ, Samtleben W, Blumenstein M, Randerson DH, Schmidt B: Clinical applications of macromolecular separations. Trans Am Soc Artif Intern Organs 27: 356, 1981PubMedGoogle Scholar
  6. 6.
    Gurland HJ, Lysaght MJ, Samtleben W, Schmidt B: Comparative evaluation of filters used in membrane plasmapheresis. Nephron 36: 173, 1984PubMedGoogle Scholar
  7. 7.
    Lysaght MJ, Samtleben W, Schmidt B, Gurland HJ: Contemporary technical issues in membrane plasmapheresis: Controversies and reconciliation. in Plasma Separation and Plasma Fractionation, edited by Lysaght MJ, Gurland HJ, Basel, Karger, 1983, p 315Google Scholar
  8. 8.
    Beaudoin G, Jaffrin MY: Plasma filtration in Couette flow membrane devices. Artif Organs 13: 43, 1989PubMedGoogle Scholar
  9. 9.
    Nydegger UE, Pflugshaupt R: Quality control of blood plasma harvested by the flat-sheet filter system Autopheresis-C. Plasma Ther Transfus Technol 7: 57, 1986Google Scholar
  10. 10.
    Lysaght MJ, Schmidt B, Samtleben W, Gurland HJ: Transport considerations in flat sheet microporous membrane plasmapheresis. Plasma Ther Transfus Technol 4: 373, 1983Google Scholar
  11. 11.
    Colton CK, Henderson LW, Ford CA, Lysaght MJ: Kinetics of hemodiafiltration. I: in vitro transport characteristics of a hollow-fiber blood ultrafilter. J Lab Clin Med 85: 355, 1975PubMedGoogle Scholar
  12. 12.
    Nicholls AJ, Platts MM: Anaphylactoid reactions due to haemodialysis, haemofiltration, or membrane plasma separation. Br Med J 285: 1607, 1982Google Scholar
  13. 13.
    Klinkmann H, Schmitt E, Falkenhagen D, Schmidt R, Osten B, Ahrenholz P, Tessenow D: Reuse of membrane plasma filters. in Plasmapheresis, edited by Nosé Y, Malchesky PS, Smith JW, Krakauer RS, New York, Raven Press, 1983, p 107Google Scholar
  14. 14.
    Randerson DH, Blumenstein M, Samtleben W, Schmidt B, Gurland HJ: Reuse of membrane plasma separators. in Plasmapheresis, edited by Nosé Y, Malchesky PS, Smith JW, Krakauer RS, New York, Raven Press, 1983, p 161Google Scholar
  15. 15.
    Bosly A, Chatelain B, Doyen C, Moriau M: Plasma exchange in Waldenstrom’s disease: efficacy and comparison of continuous centrifugation, discontinuous centrifugation, and filtration. Plasma Ther 5: 319, 1984Google Scholar
  16. 16.
    Grossman L, Benny WB, Buchanan J, Erickson RR, Buffaloe GW: Clinical evaluation of a flat-plate membrane plasma exchange system. J Clin Apheresis 1: 225, 1983PubMedGoogle Scholar
  17. 17.
    Randels J, Leitmann S, Strauss R, Nakayama S, Malchesky P: Questions and answers. J Clin Apheresis 7: 18, 1992Google Scholar
  18. 18.
    Gurland HJ, Lysaght MJ, Samtleben W, Schmidt B: A comparison of centrifugal and membrane-based apheresis formats. int J Artif Organs 7: 35, 1984PubMedGoogle Scholar
  19. 19.
    Schinzel H, Berghoff K, Beuermann I, Blank R, Weileman LS: Anticoagulation with low molecular weight heparin (Fragmin) during plasmapheresis. First experience. Ann Hematol 68(Suppl II): A72, 1994Google Scholar
  20. 20.
    Sutton DMC, Cardella CJ, Uldall PR, DeVeber GA: Complications of intensive plasma exchange. Plasma Ther 2: 19, 1981Google Scholar
  21. 21.
    Kubanek B: Risks of homologous blood transfusions. in Erythropoietin. Molecular Physiology and Clinical Applications, edited by Bauer C, Koch KM, Scigalla P, Wieczorek L, New York, Marcel Dekker, 1993, p 389Google Scholar
  22. 22.
    Roberts CG, Schindhelm K, Smeby LC, Farrell PC: Kinetic analysis of plasma separation: Use of an animal model. in Plasma Separation and Plasma Fractionation, edited by Lysaght MJ, Gurland HJ, Basel, Karger, 1983, p 25Google Scholar
  23. 23.
    Samtleben W, Randerson DH, Blumenstein M, Habersetzer R, Schmidt B, Gurland HJ: Membrane plasma exchange: principles and application techniques. J Clin Apheresis 2: 163, 1984PubMedGoogle Scholar
  24. 24.
    Frank MM, Hamburger MI, Lawley TJ, Kimberly RP, Plotz PH: Defective reticuloendothelial system Fcreceptor function in systemic lupus erythematosus. N Engl J Med 300: 518, 1979PubMedCrossRefGoogle Scholar
  25. 25.
    Lockwood CM, Worlledge S, Nicholas A, Cotton C, Peters DK: Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 300: 524, 1979PubMedCrossRefGoogle Scholar
  26. 26.
    Samtleben W, Schmidt B, Bosch T, Gurland HJ: Are immune complex assays an appropriate tool for quantitation of plasma exchange? Plasma Ther Transfus Technol 6: 523, 1985Google Scholar
  27. 27.
    Schroeder JO, Euler HH, Loeffler H: Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 107: 344, 1987PubMedGoogle Scholar
  28. 28.
    Euler HH, Krey U, Schroeder O, Loeffler H: Membrane plasmapheresis technique in rats. Confirmation of antibody rebound. J Immunol Methods 84: 313, 1985PubMedGoogle Scholar
  29. 29.
    Aufeuvre JP, Morin-Hertel F, Cohen-Solal M, Lefloch A, Baudelot J: Hazards of plasma exchange. A nationwide study of 3431 exchanges in 592 patients. in Plasma Exchange, edited by Sieberth HG, Stuttgart, New York, Schattauer, 1981, p 149Google Scholar
  30. 30.
    Das PC, Smit Sibinga CT: Complications of therapeutic plasma exchange. Lancet 2: 455, 1983PubMedGoogle Scholar
  31. 31.
    Borberg H: Problems of plasma exchange therapy. in Therapeutic Plasma Exchange, edited by Gurland HJ, Heinze V, Lee HA, Berlin, Heidelberg, New York, Springer-Verlag, 1981, p 191Google Scholar
  32. 32.
    Bussel A, Sitthy X, Reviron J: Aspects technologiques et complications des exchanges plasmatiques. (Technical aspects and complications of plasma exchange). Rev Fr Transfus Immunohematol 25: 547, 1982PubMedGoogle Scholar
  33. 33.
    Fabre M, Andreu G, Mannoni P: Some biological modifications and clinical hazards observed during plasma exchange. in Plasma Exchange, edited by Sieberth HG, Stuttgart, New York, Schattauer, 1980, p 143Google Scholar
  34. 34.
    Gajdos P, Pourrat J, Elkharrat D, Terre C: National register for plasma exchange — The French Society for Hemapheresis. Results for 1985. Plasma Ther Transfus Technol 8: 137, 1987Google Scholar
  35. 35.
    Samtleben W, Hillebrand G, Krumme D, Gurland HJ: Membrane plasma separation: clinical experience with more than 120 plasma exchanges. in Plasma Exchange, edited by Sieberth HG, Stuttgart, New York, Schattauer, 1980, p 175Google Scholar
  36. 36.
    Tindall RSA, Walker JE, Ehle AL, Near L, Rolins J, Becker D: Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone. Neurology 32: 739, 1982PubMedGoogle Scholar
  37. 37. Editorial: Hazards of apheresis. Lancet 2: 1025, 1982Google Scholar
  38. 38.
    Huestis DW: Mortality in therapeutic haemapheresis. Lancet 1: 1043, 1983PubMedGoogle Scholar
  39. 39.
    Ring J, Messmer K: Incidence and severity of anaphylactoid reactions to colloid colume substitutes. Lancet 1, 466, 1977PubMedGoogle Scholar
  40. 40.
    Evans RT, MacDonald R, Robinson EAE: Suxajnethonium apnoea associated with plasmapheresis. Anaesthesia 35: 198, 1980PubMedGoogle Scholar
  41. 41.
    Jones JV, Parker WA, Sketris IS: The effect of plasmapheresis on therapeutic drugs. Dial Transplant 14: 225, 1985Google Scholar
  42. 42.
    Sketris IS, Parker WA, Jones JV: Plasmapheresis: Its effect on toxic agents and drugs. Plasma Ther Transfus Technol 5: 305, 1984Google Scholar
  43. 43.
    Sakellarious G: Plasmapheresis as a therapy in specific forms of acute renal failure. Nephrol Dial Transplant 9(Suppl 4): 210, 1994Google Scholar
  44. 44.
    Schmidt B, Lysaght MJ, Samtleben W, Gujland HJ: Plasmapheresis without pumps for therapeutic and donor purposes. in Plasma Separation and Plasma Fractionation, edited by Lysaght MJ, Gurland HJ, Basel, Karger, 1983, p 188Google Scholar
  45. 45.
    Samtleben W, Lysaght MJ, Schmidt B, Gurland HJ: A very simple technique for spontaneous membrane plasma exchange without arterial access. Blood Purif 1: 90, 1983Google Scholar
  46. 46.
    Landini S, Coli U, Lucatello S, Fracasso A, Morachiello P, Righetto F, Scanferla F, Bazzato G: Spontaneous plasma exchange by gravity. Int J Artif Organs 7: 137, 1984PubMedGoogle Scholar
  47. 47.
    Samtleben W, Lysaght MJ, Banthien F, Hillebrand G, Gurland HJ: Simultaneous combined hemodialysis and membrane plasmapheresis. in Plasma Separation and Plasma Fractionation, edited by Lysaght MJ, Gurland HJ, Basel, Karger, 1983, p 213Google Scholar
  48. 48.
    Scheiner E, Reich L, Isaacs M, Vanamee P, Fombaum CD, van Strien S, Gulati SC: Simultaneous hemodialysis and plasmapheresis: ten years experience. (Abstract) Kidney Int 23: 160, 1983Google Scholar
  49. 49.
    Gross MLP, Baillod RA, Sweny P, Pearson RM: (Letter) Plasma Ther 2: 255, 1981Google Scholar
  50. 50.
    Lysaght MJ, Samtleben W, Schmidt B, Gurland HJ: Closed-loop plasmapheresis. in Therapeutic Hemapheresis, edited by MacPherson JL, Kasprisin DO, Boca Raton, CRC Press, 1985, Volume I, p 149Google Scholar
  51. 51.
    Samtleben W, Schindhelm K: Therapeutic plasmapheresis. (Editorial) Biomed Pharmacother 40: 281, 1986PubMedGoogle Scholar
  52. 52.
    Agishi T, Kaneko I, Hasou Y, Hayasaka Y, Sanaka T, Ota K, Abe M, Ono T, Kawai S, Yamane K: Double filtration plasmapheresis. ASAIO Trans 26: 406, 1980Google Scholar
  53. 53.
    Lysaght MJ, Samtleben W, Schmidt B, Gurland HJ: Technical assessment of membrane plasmapheresis in the treatment of a patient with IgM paraproteittemia. Clin Hemorheology 5: 27, 1985Google Scholar
  54. 54.
    Samtleben W, Schmidt B, Blumenstein M, Gurland HJ: Current status of membrane plasma separation and plasma filtration techniques. Int J Artif Organs 8(Suppl 2): 33, 1985PubMedGoogle Scholar
  55. 55.
    Busnach G, Dal-Col A, Brando B, Capelleri A, Perrino ML, Bruncati C, Minetti L: Different cascade filtration operating modalities in clinical use. Int J Artif Organs 11: 493, 1986Google Scholar
  56. 56.
    Lysaght MJ, Samtleben W, Schmidt B, Gurland HJ: Contemporary technical issues in membrane plasmapheresis: Controversies and reconciliation. in Plasma Separation and Plasma Fractionation — Current Status and Future Directions, edited by Lysaght MJ, Gurland HJ, Basel, Karger, 1983, p 315Google Scholar
  57. 57.
    Kochinke F, von Baeyer H, Schwaner I, Schwerdtfeger R: Comparison of plasmafractionation filters and filtration techniques in the clinical practise of LDL-apheresis. ASAIO Trans 32: 389, 1986Google Scholar
  58. 58.
    Valbonesi M, Lercari S, Angelini G, Malfanti L, Ferrari M, Russo E, Nati S: Cascade filtration with reverse rinse of the secondary filter. J Clin Apheresis 3: 240, 1987PubMedGoogle Scholar
  59. 59.
    Bosch T, Gurland HJ: Overview: techniques and indications of LDL-apheresis. Biomat Artif Cells Immobilization Biotechnol 19: 1, 1991Google Scholar
  60. 60.
    Legallis C, Jaffrin MY: A process enhancing selectivity and limiting plugging in plasmafractionation for ApoB removal. Int J Artif Organs 16: 108, 1993Google Scholar
  61. 61.
    Yamazaki M, Asakura H, Jokoji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Nakamura S, Naito T, Ohta H: Successful treatment of a patient with idiopathic factor VIII inhibitor with double filtration plasmapheresis and steroid administration. Blood Coagul Fibrinolysis 4: 491, 1993PubMedGoogle Scholar
  62. 62.
    Terman DS, Stewart I, Robinetti J, Carr R, Harbeck R: Specific removal of DNA antibodies in vivo with an extracorporeal immunoadsorbent. Clin Exp Immunol 24: 231, 1976PubMedGoogle Scholar
  63. 63.
    Lupien PJ, Moorjani S, Awad J: A new approach to the management of familial hypercholesterolemia: removal of plasma cholesterol based on the principle of affinity chromatography. Lancet 1: 1261, 1976PubMedGoogle Scholar
  64. 64.
    Yokoyama S, Hayashi R, Kikkawa T, Tani N, Takada S, Hatanaba K, Yamamoto A: Specific sorbent of apolipoprotein B-containing lipoproteins of plasmapheresis. Characterization and experimental use in hyper-cholesterolemic rabbits. Arteriosclerosis 4: 276, 1984PubMedGoogle Scholar
  65. 65.
    Ikonomov V, Samtleben W, Schmidt B, Blumenstein M, Gurland HJ: Adsorption profile of commercially available adsorbents: an in vitro evaluation. Int J Artif Organs 15: 312, 1992PubMedGoogle Scholar
  66. 66.
    Stoffel W, Borberg H, Greve V: Application of specific extracorporeal removal of low densitiy lipoprotein in familial hypercholesterolaemia. Lancet 2: 1005, 1981PubMedGoogle Scholar
  67. 67.
    Oette K, Borberg H: Variables involved in regression of atherosclerosis in familial hypercholesterolemic patients under long-term LDL-apheresis. Plasma Ther Transfus Technol 9: 17, 1988Google Scholar
  68. 68.
    du Moulin A, Muller-Derlich J, Bieber F, Richter WO, Frei U, Müller R, Späthe R: Antibody-based immunosorption as a therapeutic means. Blood Purif 11: 145, 1993PubMedGoogle Scholar
  69. 69.
    Samtleben W, Schmidt B, Gurland HJ: Ex vivo and in vivo Protein A perfusion; background, basic investigations, and first clinical experiences. Blood Purif 5: 179, 1987PubMedGoogle Scholar
  70. 70.
    Morrison FS, Huestis DW: Toxicity of the staphylococcal protein A immunoadsorption column. J Clin Apheresis 7: 171, 1992PubMedGoogle Scholar
  71. 71.
    Fuchs C, Windisch M, Wieland H, Armstrong VW, Rieger J, Koestering H, Scheler F, Seidel D: Selective continuous extracorporeal elimination of low-density lipoproteins from plasma by heparin precipitation without cations. in Plasma Separation and Plasma Fractionation, edited by Lysaght MJ, Gurland HJ, Basel, Karger, 1983, p 272Google Scholar
  72. 72.
    Seidel D, Armstong VW, Schuff-Werner P and the HELP Study Group: The HELP-LDL-apheresis multicentre study, an angiographically assessed trial into the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. Eur J Clin Invest 21: 375, 1991PubMedCrossRefGoogle Scholar
  73. 73.
    Seidel D (ed): HELP Report 1994. 10 Years of clinical experience. MMV Medizin Verlag Munich, 1994Google Scholar
  74. 74.
    Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D: Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr 65: 161, 1987PubMedGoogle Scholar
  75. 75.
    Armstrong VW, Schleef J, Thiery J, Muche R, Schuff-Wemer P, Eisenhauer T, Seidel D: Effect of the HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. Eur Clin J Invest 19: 235, 1989Google Scholar
  76. 76.
    Schuff-Werner P, Schütz E, Seyde WC, Eisenhauer T, Jannings G, Armstrong VW, Seidel D: Improved haemorheology associated with a reduction in plasma fibrinogen and LDL precipitation (HELP). Eur J Clin Invest 19: 30, 1989PubMedGoogle Scholar
  77. 77.
    Edelson RL, Berger CL, Gasparro FP, Jegasothy BV, Heald PW, Wintroub B, Vonderheid E, Knobler R, Wolff K, Plewig G, McKiernan G, Christiansen I, Oster M, Honigsmann H, Wilford H, Kokoschka E, Rehle T, Perez M, Stingl G, Laroche L: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 316: 297, 1987PubMedCrossRefGoogle Scholar
  78. 78.
    Christensen I, Heald P: Photopheresis in the 1990s. J Clin Apheresis 6: 216, 1991PubMedGoogle Scholar
  79. 79.
    Gurland HJ, Lysaght MJ: Future trends in renal replacement therapy. Artif Organs 17: 267, 1993PubMedCrossRefGoogle Scholar
  80. 80.
    Lockwood CM, Rees AJ, Pearson TA, Evans DJ, Peters DK, Wilson CB: Immunosuppression and plasma-exchange in the treatment of Goodpasture’s syndrome. Lancet 1:711, 1976PubMedGoogle Scholar
  81. 81.
    Lockwood CM, Rees AJ, Pinching AJ, Pussell B, Sweny P, Uff J, Peters DK: Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis. Lancet 1: 63, 1977PubMedGoogle Scholar
  82. 82.
    Pinching AJ, Peters DK, Newsom Davis J: Remission of myasthenia gravis following plasma-exchange. Lancet 2: 1373, 1976PubMedGoogle Scholar
  83. 83.
    Bukowski RM, King JW, Hewlett JS: Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 50: 413, 1977PubMedGoogle Scholar
  84. 84.
    Kambic H, Hyslop L, Nosé Y: Topics in Plasmapheresis. A Bibliography of Therapeutic Applications and New Techniques. Cleveland, ISAO Press, 1985Google Scholar
  85. 85. Conference report: Plasma exchange. Ann Rheum Dis 39: 95, 1980Google Scholar
  86. 86.
    Wysenbeck AJ, Smith JW, Krakauer RS: Plasmapheresis II: review of clinical experience. Plasma Ther 2: 61, 1981Google Scholar
  87. 87.
    Wenz B, Barland P: Therapeutic intensive plasmapheresis. Sem Hematol 18: 147, 1981Google Scholar
  88. 88.
    International Forum: What are the established clinical indications for therapeutic plasma exchange and how important is the choice of replacement for efficacy of therapeutic plasma exchange in these situations? Vox Sang 43: 270, 1982Google Scholar
  89. 89.
    Kennedy MS, Domen RE: Therapeutic apheresis: applications and future directions. Vox Sang 45: 261, 1983PubMedCrossRefGoogle Scholar
  90. 90.
    Shumak KH, Rock GA. Therapeutic plasma exchange. N Engl Med 310: 762 1984CrossRefGoogle Scholar
  91. 91.
    Council on Scientific Affairs: Current status of therapeutic plasmapheresis and related techniques. Report of the AMA panel on therapeutic plasmapheresis. JAMA 253: 819, 1985Google Scholar
  92. 92.
    Klein HG, Balow JE, Dau PC, Hamburger MI, Leitmann SF, Pineda AA, Tindall RSA: Clinical applications of therapeutic apheresis. Report of the Clinical Applications Committee. American Society for Apheresis. J Clin Apheresis 3 (special issue), 1986Google Scholar
  93. 93.
    Strauss RG, Ciavarella D, Gilcher RO, Kasprisin DO, Kiprov DD, Klein HG, McLeod BC: An overview of current management. J Clin Apheresis 8: 189, 1993PubMedGoogle Scholar
  94. 94.
    Fish AJ, Lockwood MC, Wong M, Price RG: Detection of Goodpasture antigen in fractions prepared from collagenase digest of human glomerular basement membrane. Clin Exp Immunol 55: 58, 1984PubMedGoogle Scholar
  95. 95.
    Wieslander J, Byrgen P, Heinegard D: Isolation of the specific glomerular basement membrane antigen involved in Goodpasture syndrome. Proc Nail Acad Sci USA 81: 1544, 1984Google Scholar
  96. 96.
    Salant DJ: Immunopathogenesis of crescentic glomerulonephritis and lung purpura (Nephrology Forum). Kidney Int 32: 408, 1987PubMedGoogle Scholar
  97. 97.
    Wilson CB, Dixon FJ: Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 3: 74, 1973PubMedGoogle Scholar
  98. 98.
    Wilson CB, Dixon FJ: The renal response to immunological injury. in The Kidney, edited by Brenner BM, Rector FC, Philadelphia, London, Toronto, Saunders, 1981, p 1237Google Scholar
  99. 99.
    Rees AJ, Lockwood CM, Peters DK: Nephritis due to antibodies to GBM. in Progress in Glomerulonephritis, edited by Kincaid-Smith P, D’Apice AJF, Atkins RJ, New York, John Wiley, 1980, p 348Google Scholar
  100. 100.
    Lockwood CM, Pusey CD, Peters DK: Indications for plasma exchange: renal diseases. in Plasma Separation and Plasma Fractionation, edited by Lysaght MJ, Gurland HJ, Basel, Karger, 1983, p 145Google Scholar
  101. 101.
    Swainson CP, Winney RJ, Urbaniak SJ, Robinson JS: Plasma exchange in severe glomerulonephritis — who benefits? Proc Eur Dial Transplant Assoc 19: 732, 1982Google Scholar
  102. 102.
    Herody M, Bobrie G, Gouarin C, Grünfeld JP, Noel LH. Anti-GBM disease: Predictive value of clinical, histological and serological data. Clin Nephrol 40: 249, 1993PubMedGoogle Scholar
  103. 103.
    Johnson JP, et al.: Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine 64: 219, 1985PubMedGoogle Scholar
  104. 104.
    Peters DK, Pusey CD, Lockwood CM: Immunomodulation by plasma exchange: therapeutic objectives. in Plasma Separation and Plasma Fractionating, edited by Lysaght MJ, Gurland HJ, Basel, Karger, 1983, p 1Google Scholar
  105. 105.
    Flores JC, Savage COS, Lockwood CM, Taube D, Cameron JS, Williams DG, Ogg CS: Clinical and immunological evolution of oligoanuric anti-GBM nephritis by haemodialysis. Lancet 1: 5, 1986PubMedGoogle Scholar
  106. 106.
    Rees AJ, Lockwood CM, Peters DK: Enhanced allergic tissue injury in Goodpasture’s syndrome by intercurrent infection. Br Med J 2: 723, 1977PubMedGoogle Scholar
  107. 107.
    Rees AJ, Pusey CD: Plasma exchange in systemic vasculitis. Netherlands J Medicine 36: 103, 1990Google Scholar
  108. 108.
    Kauffmann RH, van Es LA, Daha MR: The specific detection of IgA immune complexes. J Immunol Meth 40: 117, 1981Google Scholar
  109. 109.
    Valentijn RM, Kauffmann RH, De La Riviere GB, Daha MR, van Es LA: Presence of circulating macrdmolecular IgA in patients with hematuria due to primary IgA nephropathy. Am J Med 74: 375, 1983PubMedGoogle Scholar
  110. 110.
    Hene RJ, Kater L: Plasmapheresis in nephritis associated with Henoch-Schoenlein purpura and in primary IgA nephropathy. Plasma Ther Transfus Technol 4: 165, 1983Google Scholar
  111. 111.
    Samtleben W, Gurland HJ: Plasma exchange in nephrological diseases. in Therapeutic Hemapheresis, edited by Valbonesi M, Pineda AA, Biggs JC, Milano, Wichtig Editore, 1986, p 29Google Scholar
  112. 112.
    Nicholls K, Becker G, Walker R, Wright C, Kincaid-Smith P: Plasma exchange in progressive IgA nephropathy. J Clin Apheresis 5: 128, 199Google Scholar
  113. 113.
    Chalopin JM, Tanter Y, Wenning H: Immunosuppression and plasma exchange in dense deposit disease. Abstracts Annalesde Medicine Interne 135 (special issue): 31, 1984Google Scholar
  114. 114.
    Couser WG, Salant DJ: In situ immune complex formation and glomerular injury. Kidney Int 17: 1, 1980PubMedGoogle Scholar
  115. 115.
    Schwarzt RS: Immunologic and genetic aspects of systemic lupus erythematosus. Kidney Int 19: 474, 1981Google Scholar
  116. 116.
    Jones JV, Cumming RH, Bucknall RC, Asplin CM, Fraser ID, Bothamley J, Davis P, Hamblin TJ: Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1: 709, 1976PubMedGoogle Scholar
  117. 117.
    Samtleben W, Lysaght MJ, Gurland HJ: Plasma exchange in lupus nephritis: Rationale and clinical experiences. Dial Transplant 14: 213, 1985Google Scholar
  118. 118.
    Austin HA, Klippel JH, Balow JE, Le Riche NIGH, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314; 614, 1986PubMedCrossRefGoogle Scholar
  119. 119.
    Wei N, Kippel JH, Huston DP, Hall RP, Lawley TJ, Balow JE, Steinberg AD, Decker JL: Randomized trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1: 17, 1983PubMedGoogle Scholar
  120. 120.
    Clark WF, Balfe JW, Cattran DC, Williams W, Koval JJ, Arnott M, Chodirker WB, Lindsay RM, Linton AL: Long-term plasma exchange in patients with systemic lupus erythematosus and diffuse proliferative glomerulonephritis. Plasma Ther Transfus Technol 5: 353, 1984Google Scholar
  121. 121.
    Lewis EJ, Hunsicker LG, Lan S-P, Rohde RD, Lachin JM: A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 326: 1373, 1992PubMedCrossRefGoogle Scholar
  122. 122.
    Euler HH, Schroeder JO, Zeuner RA, Teske E: A randomized trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: design of the LPSG trial. Int J Artif Organs 14: 639, 1991PubMedGoogle Scholar
  123. 123.
    Euler HH, Loeffler H, Chrisophers E: Synchronization of plasmapheresis and pulse cyclophosphamide in pemphigus vulgaris. Arch Dermatol 123: 1205, 1987PubMedGoogle Scholar
  124. 124.
    Guillevin L, Le Thi Huong Du, Godeau P, Jais P, Wechsler B: Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. Br J Rheumatol 27, 258, 1988PubMedGoogle Scholar
  125. 125.
    Remuzzi G: HUS and TTP: Variable expressions of a single entity. Kidney Int 32: 292, 1987PubMedGoogle Scholar
  126. 126.
    Neild G: The haemolytic uremic syndrome: a review. Q J Med 241: 367, 1987Google Scholar
  127. 127.
    Aster RH: Plasma therapy for thrombotic thrombocytopenic purpura. Sometimes it works, but why (Editorial retrospective). N Engl J Med 312: 985, 1985PubMedCrossRefGoogle Scholar
  128. 128.
    Rizzoni G, Pavanelle L, Claris-Appiani A, Edefonti A, Facchin P, Ranchini F, Gussmano R, Imbasciati E, Perfumo F, Remuzzi G: Treatment of children with hemolytic uremic syndrome (HUS) with plasma: a multicenter controlled trial. (Abstract) Helv Paediatr Acta 41: 114, 1986Google Scholar
  129. 129.
    Stoffner D, Banthien FCA, Habersetzer R, Samtleben W, Clemm C, Unterburger P, Zaehringer J, Gurland HJ: Plasma exchange and concommitant therapy in TTP. Int J Artif Organs 7: 223, 1984PubMedGoogle Scholar
  130. 130.
    Byrnes JJ, Moake JL, Klug P, Periman P: Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 34: 169, 1990PubMedGoogle Scholar
  131. 131.
    Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannio NM, Azocar J, Seder RH, Hong SL, Deykin D: Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307: 1432, 1982PubMedCrossRefGoogle Scholar
  132. 132.
    Bell WR, Braine HG, Ness PM, Kickler TS: Improved survival in thrombotic thrombocytopenic purpura — hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 325: 398, 1991PubMedCrossRefGoogle Scholar
  133. 133.
    Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA, and the Canadian Apheresis Study Group: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325: 393, 1991PubMedCrossRefGoogle Scholar
  134. 134.
    Pourrat JP, Dueymes JM, Conte JJ, Pourrat O, Alcalay D, Touchard G, Patte D: Plasma exchange in myeloma renal failure. in Plasmapheresis, edited by Nosé Y, Malchesky PS, Smith JW, Krakauer RS, New York, Raven Press, 1983, p 349Google Scholar
  135. 135.
    Blumenstein M, Samtleben W, Gurland HJ: Die Behandlung des paraproteinämischen Nierenversagens mit Plasmapherese. (Plasma therapy for treatment of renal failure in patients with plasma cell diseases). Nieren-und Hochdruck 16: 140, 1987Google Scholar
  136. 136.
    Blumberg A, Buergi W, Marti HR: Plasmapheresebe-handlung bei multiplem Myelom mit Niereninsuffizienz. (Plasmapheresis therapy for multiple myeloma with renal insufficiency). Schweiz Med Wochenschr 113: 398, 1983PubMedGoogle Scholar
  137. 137.
    Zucchelli P, Pasquali S, Cagnoli L, Ferrari G: Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 33: 1175, 1988PubMedGoogle Scholar
  138. 138.
    Mason PD, Pusey CD: Plasma exchange in nephrological diseases. Curr Stud Hematol Bllod Transfus 57: 152, 1990Google Scholar
  139. 139.
    Hillebrand G, Castro LA, Samtleben W, Albert E, Scholz S, Illner WD, Land W, Gurland HJ: Removal of preformed cytotoxic antibodies in highly sensitized patients using plasma exchange and immunosuppressive therapy, azathioprine, or cyclosporine prior to renal transplantation. Transplant Proc 18: 1033, 1986Google Scholar
  140. 140.
    Minakuchi J, Takahashi K, Toma H, Teroaka S, Hayasaka Y, Ota K: Removal of preformed antibodies by plasmapheresis prior to kidney transplantation. Transplant Proc 18: 1083, 1986Google Scholar
  141. 141.
    Palmer A, Welsh K, Gjorstrup P, Taube D, Bewick M, Thick M: Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet i:10, 1989Google Scholar
  142. 142.
    Kupin WL, Venkat KK, Hayashi H, Mozes MF, Oh HK, Watt R: Removal of lymphocytotoxic antibodies by pre-transplant immunoadsorption therapy in highly sensitized renal transplant recipients. Transplantation 51: 324, 1991PubMedGoogle Scholar
  143. 143.
    Swanepoel CR, Cassidy MJD, May M, Oudshoorn M, du Toit E, Wood L, Jacobx P: Reactivity of pretransplant cytotoxic antibodies to a selected HLA panel is not influenced by cyclosporin A, with or without plasma exchange. J Clin Apheresis 6: 28, 1991PubMedGoogle Scholar
  144. 144.
    Gurland HJ, Blumenstein M, Lysaght MJ, Samtleben W, Stoffner D: Plasmapheresis in renal transplantation. Kidney Int 23(Suppl 14): S82, 1983Google Scholar
  145. 145.
    Cardella CJ, Sutton DMC, Uldall PR, Cook GT, de Veber GA: Factors influencing the effect of intensive plasma exchange on acute transplant rejection. Transplant Proc 17: 2777, 1985Google Scholar
  146. 146.
    Bonomini V, Vangelista A, Frasca GM, Di Felice A, Liviano D’Arcangelo G: Effects of plasmapheresis in renal transplant rejection. A controlled study. in Therapeutic Plasma Exchange and Selective Plasma Separation, edited by Bambauer R, Malchesky PS, Falkenhagen D, Stuttgart, New York, 1987, p 69Google Scholar
  147. 147.
    Li P, Lai F, Leung C, Lui S, Wang A, Lai K. Plasma exchange in the treatment of early recurrent focal glomerulosclerosis after renal transplantation. Am J Nephrol 13: 289, 1993PubMedGoogle Scholar
  148. 148.
    Glassock RJ: Therapy of idiopathic nephrotic syndrome in adults. Am J Nephrol 13: 422, 1993PubMedGoogle Scholar
  149. 149.
    Denti E, Walker JM: Activated carbon: properties, selection and evaluation. in Sorbents and Their Clinical Applications, edited by Giordano C, New York, Academic Press Inc, 1980, p 101Google Scholar
  150. 150.
    Denti E, Luboz MP, Tessore V: Adsorption characteristics of cellulose acetate coated charcoals. J Biomed Mater Res 9: 143, 1975PubMedGoogle Scholar
  151. 151.
    Chang TMS: Semipermeable aqueous microcapsules (artifical cells): with emphasis on experiments in an extracorporeal shunt system. Trans Am Soc Artif Intern Organs 12: 13, 1966PubMedGoogle Scholar
  152. 152.
    Chang TMS: Microcapsule artificial kidney in replacement of renal function. With emphasis on adsorbent hemoperfusion. in Replacement of Renal Function by Dialysis, First Edition, edited by Drukker W, Parsons FM, Maher JF. The Hague, Boston, London, Martinus Nijhoff, 1978, p 217Google Scholar
  153. 153.
    Craddock PR, Fehr J, Brigham KL, Kronenherg R, Jacobs HS: Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 296: 769, 1977PubMedCrossRefGoogle Scholar
  154. 154.
    Winchester JF, Ratcliffe JG, Carlyle E, Kennedy AC: Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia. Kidney Int 14: 74, 1978PubMedGoogle Scholar
  155. 155.
    Weston MJ, Langley PG, Rubin MH, Hanid MA, Mellon P, Williams R: Platelet function in fulminant hepatic failure and effect of charcoal haemoperfusion. Gut 18: 897, 1977PubMedGoogle Scholar
  156. 156.
    Winchester JF, Forbes CD, Courtney JM, Reavey M, Prentice CRM: Effect of sulphinpyrazone and aspirin on platelet adhesion to activated charcoal and dialysis membranes in vitro. Thromb Res 11: 443, 1977PubMedGoogle Scholar
  157. 157.
    Gimson AES, Langley PG, Hughes RD, et al.: Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet 1: 173, 1980PubMedGoogle Scholar
  158. 158.
    Chang TMS, Chirito E, Bane B, Cole C, Hewish M: Clinical performance-characteristics of a new combined system for simultaneous hemoperfusion-hemodialysis-ultrafiltration in series. Trans Am Soc Artif Intern Organs 21:502, 1975PubMedGoogle Scholar
  159. 159.
    Stefoni S, Coli L, Feliciangeli G, Baldrati L, Bonomini V: Regular hemoperfusion in regular dialysis treatment. A longterm study. Int J Artif Organs 3: 348, 1980PubMedGoogle Scholar
  160. 160.
    Muirhead EE, Reid AF: Resin artificial kidney. J Lab Clin Med 33: 841, 1948PubMedGoogle Scholar
  161. 161.
    Schreiner GE: The role of hemodialysis (artificial kidney) in acute poisoning. Arch Intern Med 102: 896. 1958Google Scholar
  162. 162.
    Yatzidis H: A convenient haemoperfusion microapparatus over charcoal for the treatment of endogenous and exogenous intoxications. Its use as an artificial kidney Proc Eur Dial Transplant Assoc 1: 83, 1964Google Scholar
  163. 163.
    Yatzidis H, Voudiclari S, Oreopoulos D, Tsaparas N, Triantaphyllidis D, Gavras C, Stavroulaki A: Treatment of severe barbiturate poisoning. Lancet 2: 216, 1965Google Scholar
  164. 164.
    Dunea G, Kolff WJ: Clinical experience with the Yatzidis charcoal artificial kidney. Trans Am Soc Artif Intern Organs 11: 178, 1965PubMedGoogle Scholar
  165. 165.
    Chang TMS, Gonda A, Dirks JH, Malave N: Clinical evaluation of chronic intermittent and short term hemoperfusion in patients with chronic renal failure using semipermeable microcapsules (artificial cells) formed from membrane coated activated charcoal. Trans Am Soc Artif Intern Organs 17: 246, 1971PubMedGoogle Scholar
  166. 166.
    Asaba H: Uremic middle molecules. Accumulation, renal excretion and elimination by extracorporeal treatment. Scand J Urol Nephrol 67(Suppl): 1, 1982Google Scholar
  167. 167.
    Bonomini V, Stefoni S, Feliciangeli G, Coli L, Scolari MP, Orsi C, Nanni Costa A, Prandini R, Galanti S: Shortened treatment time by combined hemodialysis and hemoperfusion. Contrib Nephrol 44: 57, 1985PubMedGoogle Scholar
  168. 168.
    Henderson IS, Kennedy AC: Long-term evaluation of charcoal haemoperfusion combined with dialysis for uraemic patients. in Biomaterials in Artificial Organs, edited by Paul JP, Gaylor JDS, Courtney JM, Gilchrist T, London, Basingstoke, The Macmillan Press Ltd, 1984, p 72Google Scholar
  169. 169.
    Chang TMS, Barre P, Kuruvilla S: Long-term reduced time hemoperfusion-hemodialysis compared to standard dialysis. A preliminary crossover analysis. Trans Am Soc Artif Intern Organs 31: 572, 1985PubMedGoogle Scholar
  170. 170.
    Chang TMS, Barre P: Effect of desferrioxamine on removal of aluminium and iron by coated charcoal haemoperfusion and haemodialysis. Lancet 2: 1051, 1983PubMedGoogle Scholar
  171. 171.
    Hakim RM, Schulman JM, Lazarus JM: Hemoperfusion in the treatment of aluminum (Al) and iron (Fe) induced bone disease. Abstracts Am Soc Nephrol 18: 65A, 1985Google Scholar
  172. 172.
    Winchester JF: Management of iron overload. Semin Nephrol 4(Suppl 1): 22, 1986Google Scholar
  173. 173.
    Vasilakakis DM, D’Haese PC, Lamberts LV, Lemoniatou E, Digenis PN, De Broe ME: Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis. Kidney Int 41: 1400, 1992PubMedGoogle Scholar
  174. 174.
    Litovitz TL, Clark LR, Soloway RA: 1993 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. J Am Emerg Med 12: 546, 1994Google Scholar
  175. 175.
    Clemmesen C, Nilsson E: Therapeutic trends in the treatment of barbiturate poisoning: the Scandinavian method. Clin Pharmacol Ther 2: 220, 1961PubMedGoogle Scholar
  176. 176.
    Winchester JF, Gelfand MC, Tilstone WJ: Hemoperfusion in drug intoxication — clinical and laboratory aspects. Drug Metab Rev 8: 69, 1978PubMedGoogle Scholar
  177. 177.
    Maher JF, Schreiner GE: The dialysis of poisons and drugs. Trans Am Soc Artif Intern Organs 13: 369, 1967Google Scholar
  178. 178.
    Winchester JF, Gelfand MC, Knepshield JH, Schreiner GE: Dialysis and hemoperfusion of poisons and drugs — update. Trans Am Soc Artif Intern Organs 23: 762, 1977PubMedGoogle Scholar
  179. 179.
    Cohan SL, Winchester JF, Gelfand MC: Treatment of intoxications by charcoal hemadsorption. Drug Metab Rev 13: 681, 1982PubMedGoogle Scholar
  180. 180.
    Rosenbaum JL, Kramer MS, Raja RM, Krug MJ, Boliday CG: Current status of hemoperfusion in toxicology. Clin Toxicol 17: 493, 1980PubMedCrossRefGoogle Scholar
  181. 181.
    Cutler RE, Forland SC, Hammond PG, Evans JR: Extra-corporeal removal of drugs and poisons by hemodialysis and hemoperfusion. Annu Rev Pharmacol Toxicol 27: 169, 1987PubMedGoogle Scholar
  182. 182.
    Winchester JF, Tilstone WJ, Edwards RO, Gilchrist T, Kennedy AC: Hemoperfusion for enhanced drug elimination — a kinetic analysis in paracetamol poisoning. Trans Am Soc Artif Intern Organs 20: 358, 1974Google Scholar
  183. 183.
    Verpooten GA, De Broe ME: Combined hemoperfusion-hemodialysis in severe poisoning: kinetics of drug extraction. Resuscitation 11: 275, 1984PubMedGoogle Scholar
  184. 184.
    Winchester JF, Rahman A, Tilstone WJ, Kessler A, Mortensen L, Schreiner GE, Schein PS: Sorbent removal of adriamycin in vitro and in vivo. Cancer Treat Rep 63: 1787, 1979PubMedGoogle Scholar
  185. 185.
    Pond S, Rosenberg J, Benowitz NL, Takki S: Pharmacokinetics of haemoperfusion in drug overdose. Clin Pharmacokinet 4: 329, 1979PubMedGoogle Scholar
  186. 186.
    Gelfand MC, Winchester JF, Knepshield JH, Hanson KM, Cohan SL, Strauch BS, Geoly KL, Kennedy AC, Schreiner GE: Treatment of severe drug overdose with charcoal hemoperfusion. Trans Am Soc Artif Intern Organs 23: 599, 1977PubMedGoogle Scholar
  187. 187.
    Gibson TP, Lucas SV, Nelson HA, Atkinson AJ, Okita GT, Ivanovich P: Hemoperfusion removal of digoxin from dogs. J Lab Clin Med 91: 673, 1978PubMedGoogle Scholar
  188. 188.
    Lorch JA, Garella S: Hemoperfusion to treat intoxications. Ann Intern Med 91: 301, 1979PubMedGoogle Scholar
  189. 189.
    Uldall PR: Controlled trial of resin hemoperfusion for the treatment of drug overdose at Toronto Western Hospital (TWH). Trans Am Soc Artif Intern Organs 28: 676, 1982Google Scholar
  190. 190.
    Winchester JF: Active Methods for Detoxification: oral sorbents, forced diuresis, hemoperfusion and hemodialysis. in Clinical Management of Poisoning and Drug Overdose, Second Edition, edited by Haddad LM, Winchester, JF, WB Saunders Co, Philadelphia, PA, 1990, p 148Google Scholar
  191. 191.
    Winchester JF, Gelfand MC, Helliwell M, Vale JA, Goulding R, Schreiner GE: Extracorporeal treatment of salicylate or acetaminiphen poisoning — is there a role? Arch Intern Med 141: 370, 1981PubMedGoogle Scholar
  192. 192.
    Diaz-Buxo JA, Farmer CD, Chandler TY: Hemopertusion in the treatment of amitriptyline poisoning. Trans Am Soc Artif Intern Organs 24: 699, 1978PubMedGoogle Scholar
  193. 193.
    Maini R, Winchester JF: Removal of paraquat from blood by haemoperfusion over sorbent materials. Br Med J 3: 281, 1975PubMedGoogle Scholar
  194. 194.
    Okonek S, Weilemann LS, Majdandzic H et al.: Successful treatment of paraquat poisoning: Activated charcoal per os and ‘continuous hemoperfusion’. J Toxicol Clin Toxicol 19: 807, 1982PubMedGoogle Scholar
  195. 195.
    Proudfoot AT: Predictive value of early plasma paraquat concentrations. in Paraquat Poisoning, Mechanisms, Prevention, Management, edited by C Bismuth, AH Hall, New York, Marcel Dekker, 1995, p 275Google Scholar
  196. 196.
    Winchester JF, Rahman A, Bregman H, Mortensen LM, Gelfand MC, Schein PS, Schreiner GE: Role of hemoperfusion in anticancer drug removal. in Hemoperfusion, Kidney and Liver Support and Detoxification, edited by Sideman S, Chang TMS, Washington DC, Hemisphere Publishing Corp, 1980, p 369Google Scholar
  197. 197.
    Hande KR, Balow JE, Draje JC, Rosenberg SA, Chabner BA: Methotrexate and hemodialysis. Ann Intern Med 87: 496, 1977Google Scholar
  198. 198.
    Molina R, Fahian C, Cowley B Jr: Use of charcoal hemoperfusion to reduce serum methotrexate levels in a patient with acute renal insufficiency. Am J Med 82: 350, 1987PubMedGoogle Scholar
  199. 199.
    Oldfield EH, Dedrick RL, Yeager RL, Clark WC, DeV-room HL, Chatterji DC, Doppman JL: Reduced systemic drug exposure by continuous intra-arterial chemotherapy with hemoperfusion of regional venous drainage. J Neurosurg 163: 726, 1985Google Scholar
  200. 200.
    Ku Y, Fukumoto T, Iwasaki T et al.: Clinical pilot study on high-dose intra-arterial chemotherapy with direct hemoperfusion under hepatic venous isolation in patients with advanced hepatocellular carcinoma. Surgery 117: 510, 1995PubMedGoogle Scholar
  201. 201.
    Shah G, Nelson HA, Atkinson AJ, Okita GT, Ivanovich P, Gibson TP: Effect of hemoperfusion on the pharmacokinetics of digitoxin in dogs. J Lab Clin Med 93: 370, 1979PubMedGoogle Scholar
  202. 202.
    Marbury T, Mahoney J, Juncos L, Conti R, Cade R: Advanced digoxin toxicity in renal failure — treatment with charcoal hemoperfusion. South Med J 72: 279, 1979PubMedGoogle Scholar
  203. 203.
    Hoy WE, Gibson TP, Rivero AJ, Jain JK, Talley TT, Bayer RM, Montondo DF, Freeman RB: XAD-4 resin hemoperfusion for digitoxic patients with renal failure. Kidney Int 23: 79, 1983PubMedGoogle Scholar
  204. 204.
    Slattery JR, Koup JR: Hemoperfusion in the management of digoxin toxicity. Is it warranted? Clin Pharmacokinet 4: 395, 1979PubMedGoogle Scholar
  205. 205.
    Wenger TL, Butler VP Jr, Haber E, Smith TW: Treatment of 63 severely digitalis-toxic patients with digoxin specific antibody fragments. J Am Coll Cardiol 5(Isl Suppl A): 118A, 1985PubMedCrossRefGoogle Scholar
  206. 206.
    Ujhelyi MR, Robert S, Cummings DM, Colucci RD, Sailstad JM, Vlasses PH, Findlay JWA, Zarowitz BJ: Disposition of digoxin immune Fab in patients with kidney failure. Clin Pharmacol Ther 54: 388, 1993PubMedCrossRefGoogle Scholar
  207. 207.
    Worth DP, Davison AM, Lewins AM, Ledgerwood MJ, Taylor A: Haemodialysis and charcoal haemoperfusion in acute inorganic mercury poisoning. Postgrad Med J 60: 636, 1984PubMedGoogle Scholar
  208. 208.
    De Backer W, Zachee P, Verpooten GA, Majelyne W, Vanheule A, De Broe ME: Thallium intoxication treated with combined hemoperfusion-hemodialysis. J Toxicol Clin Toxicol 19: 259, 1982PubMedGoogle Scholar
  209. 209.
    De Groot, van Heijst AN, van Kesteren RG, Maes RA: An evaluation of the efficacy of charcoal haemoperfusion in the treatment of three cases of acute thallium poisoning. Arch Toxicol 57: 61Google Scholar
  210. 210.
    Lund ME, Banner W, Clarkson TW, Berlin M: Treatment of acute methylmercury ingestion by hemodialysis with n-acetylcysteine (Mucomyst) infusion and 2,3-dimercaptopropane sulfonate. J Toxicol Clin Toxicol 22: 31, 1984PubMedCrossRefGoogle Scholar
  211. 211.
    Al-Abassi AH, Kostyniak PJ, Clarkson TW: An extracorporeal complexing hemodialysis system for the treatment of methylmercury poisoning. III. Clinical applications. J Pharmacol Exp Ther 207: 249, 1978Google Scholar
  212. 212.
    Margel S: A novel approach for heavy metal poisoning treatment, a model. Mercury poisoning by means of chelating microspheres: hemoperfusion and oral administration. J Med Chem 24: 1263, 1981PubMedGoogle Scholar
  213. 213.
    Banner W, Koch M, Capin DM, Hopf SB, Chang S, Tong TG: Experimental chelation therapy in chromium. Iead and boron intoxication with n-acetylcysteine and other compounds. Toxicol Appl Pharmacol 83: 142, 1986PubMedGoogle Scholar
  214. 214.
    Zieve L, Doizeki WM, Zieve FJ: Synergism between mercaptans and ammonia or fatty acids in the production of coma; a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 83: 16, 1974PubMedGoogle Scholar
  215. 215.
    James TH, Ziparo V, Jeppsson B, Fischer JE: Hyperammonaemia, plasma amino acid imbalance, and blood-brain amino acid transport: a unified theory of portalsystemic encephalopathy. Lancet 2: 772, 1979PubMedGoogle Scholar
  216. 216.
    Schafer DF, Jones EA: Hepatic encephalopathy and the gamma-aminobutyric-acid neurotransmitter system. Lancet 1: 18, 1982PubMedGoogle Scholar
  217. 217.
    Chang TMS: Haemoperfusion over microencapsulated adsorbent in a patient with hepatic coma. Lancet 2: 1371, 1972PubMedGoogle Scholar
  218. 218.
    Gazzard BG, Portmann BA, Weston MJ, Langley PG, Murray-Lyon IM, Dunlop EH, Flax H, Mellon PJ, Record CO, Ward MB, Williams R: Charcoal haemoperfusion in the treatment of fulminant hepatic failure. Lancet 1: 1301, 1974PubMedGoogle Scholar
  219. 219.
    Chang TMS: Hemoperfusion alone and in series with ultrafiltration or dialysis for uremia, poisoning and liver failure. Kidney Int 10(Suppl 7): S305, 1976Google Scholar
  220. 220.
    Bartels O, Neidhardt B, Neidhardt M, Schellberger H, Issel W, Waldherr AM, Demling L: Untersuchungen und Entahrungen mit der Kohlehaemoperfusion bei Leberkoma. in Entgiftung mit Hamoperfusion (Investigation and experience with carbon hemoperfusion for liver coma. in Detoxification by Hemoperfusion), edited by Demling L, Bartels O, Freiburg, Bundernagel-Verlag, 1977, p 119Google Scholar
  221. 221.
    Bartels O, Neithardt M, Schellberger H: Hormone losses by charcoal haemoperfusion. in Artificial Liver Support, edited by Brunner G, Schmidt FW, Berlin, Springer-Verlag, 1981, p 121Google Scholar
  222. 222.
    Gimson AES, Braude S, Mellon PJ, Canalese J, Williams R: Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 2: 681, 1982PubMedGoogle Scholar
  223. 223.
    Cordopatri F, Boncinelli S, Marsili M, Lorenzi P, Fabbri LP, Paci P, Salvadori M, Morhni M, Cinoti S, Casparini P: Effects of charcoal haemoperfusion with prostacyclin on the coagulation-fibrinolysis system and platelets of patients with fulminant hepatic failure — preliminary observation. Int J Artif Organs 5: 243, 1982PubMedGoogle Scholar
  224. 224.
    Williams R: Fulminant hepatic failure. Postgrad Med J 59(Suppl 4): 33, 1983PubMedGoogle Scholar
  225. 225.
    Bihari D, Hughes RD, Gimson AES, Langley PG, Ede RJ, Eder G, Williams R: Effects of serial resin haemoperfusion in fulminant hepatic failure. Int J Artif Organs 6: 299, 1983PubMedGoogle Scholar
  226. 226.
    O’Grady JG, Gimson AE, O’Brien CJ, Pucknell A, Hughes RD, Williams R: Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 94: 1186, 1988PubMedGoogle Scholar
  227. 227.
    Rozga J, Hozman MD, Ro MS, et al.: Development of a hybrid bioartificial liver. Ann Surg 217: 502, 1993PubMedGoogle Scholar
  228. 228.
    Rozga J, Podesta L, LePage E, et al.: Control of cerebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure. Lancet 342: 898, 1993PubMedGoogle Scholar
  229. 229.
    Rozga J, Hozman MD, Ro MS et al.: Development of reliable artificial liver support (ALS) — plasma exchange in combination with hemodialfiltration using high-performance membranes. Dig Dis Sci 38: 469, 1993Google Scholar
  230. 230.
    Fix IJ, Langnas AN, Fristoe, LW et al.: Successful application of extracorporeal liver perfusion: a technology whose time has come. Am J Gastroenterol 88: 1876, 1993Google Scholar
  231. 231.
    Sussman NL, Gislason GT, Kelly JH: Extracorporelal liver support. Application to fulminant hepatic failure. J Clin Gastroenterol 18: 320, 1994PubMedGoogle Scholar
  232. 232.
    Maeda K, Asada H, Yamamoto Y, Ohta K: Psoriasis treatment with direct hemoperfusion. in Hemoperfusion, Kidney and Liver Support and Detotification, edited by Sideman S, Chang TMS, Washington DC, Hemisphere Publishing Corp, 1980, p 349Google Scholar
  233. 233.
    Kolff WJ: Dialysis of schizophrenics. Weird and novel applications of dialysis, hemofiltration, hemoperfusion, and peritoneal dialysis: Witchcraft? Artif Organs 2: 277, 1978PubMedGoogle Scholar
  234. 234.
    Schulz SC, VanKammen DP, Balow JE, Flye NW, Bunney WE: Dialysis in schizophrenia: a double blind evaluation. Science 211: 1060, 1981Google Scholar
  235. 235.
    Nissensson AB, Rapaport M, Gordon A, Narins RG: Controlled study demonstrates that psoriasis is not improved by hemodialysis. Kidney Int 14: 682, 1978Google Scholar
  236. 236.
    Terman DS: Extracorporeal immunoadsorbents for extraction of circulating immune reactants. in Sorbents and Their Clinical Applications, edited by Giordano C, New York, Academic Press Inc, 1980, p 470Google Scholar
  237. 237.
    Terman DS, Buffaloe G, Mattioli C, Cook G, Tillquist R, Sullivan M, Ayus JC: Extracorporeal immunoabsorption: initial experience in human systemic lupus erythematosus. Lancet 2: 824, 1979PubMedGoogle Scholar
  238. 238.
    Terman DS, Garcia-Rinaldi R, McCalman R, Crumb CC, Mattioli C, Cook G, Poser R: Modification of hyperacute renal xenograft rejection after extracorporeal immunoadsorption of heterospecific antibody. Int J Artif Organs 2: 35, 1979PubMedGoogle Scholar
  239. 239.
    Hakim, RM, Milford E, Himmelfarb J, Wingard R, Lazarus JM, Watt RM: Extracorporeal removal of anti-HLA antibodies in transplant candidates. Am J Kidney Dis 16: 423, 1990PubMedGoogle Scholar
  240. 240.
    Wingard, RL, Lee WO, Hakim RO: Extracorporeal treatment of familial hypercholesterolemia with monoclonal antibodies to low-density lipoproteins. Am J Kidney Dis 18: 559, 1991PubMedGoogle Scholar
  241. 241.
    Savin H, Marcus L, Margel S, Ofarim M, Ravid M: Treatment of adverse digitalis effects by hemoperfusion through columns with antidigoxin antibodies bound to agarose polyacrolein microsphere beads. Am Heart J 113: 1078, 1987PubMedGoogle Scholar
  242. 242.
    Brizgys, MV, Pincus S, Siebert CJ, Rollins DE. Removal of digoxin from circulation using immobilized monoclonal antibodies. J Pharm Sci 78: 393, 1989PubMedGoogle Scholar
  243. 243.
    Terman DS, Yamamoto T, Mattioli M, Cook G, Tillquis R, Henry J, Poser Daskal Y: Extensive necrosis of spontaneous canine mammary adenocarcinoma aftce extracorporeal perfusion over Staphylococcus aureus Cowans I. J Immunol 124: 795, 1980PubMedGoogle Scholar
  244. 244.
    Terman DS, Betram HJ: Antitumor effects of immobilized protein A and Staphylococcal products: linkage between toxicity and efficacy and tumoricidal reagents. Eur J Cancer Clin Oncol 121: 1115, 1985Google Scholar
  245. 245.
    Langone JJ, Das C, Bennett D, Terman DS: Generation of human C1, C3a, and C4a anaphylotoxin by protein A of Staphylococcus aureus and immobilized protein A reagents in serotherapy of cancer. J Immunol 133: 1057, 1984PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Hans Gurland
    • 1
  • Walter Samtleben
    • 2
  • Michael J. Lysaght
    • 3
  • James F. Winchester
    • 4
  1. 1.Nephrology Division Medical Department IKlinikum GrosshadernMunich 70Germany
  2. 2.Nephrology Division Medical Department I. Klinikum GrosshadernUniversity of MunichMünchenGermany
  3. 3.Division of Biology and MedicineBrown UniversityUSA
  4. 4.Department of NephrologyGeorgetown University Medical CenterWashington, DCUSA

Personalised recommendations